Can GLP-1 Drugs Slow Parkinson’s Disease? Evidence from 5 Trials
Research Highlights GLP-1 receptor agonists are diabetes drugs (Ozempic, Trulicity, Byetta) being tested in Parkinson’s disease for possible disease-modifying effects. The hypothesis: shared metabolic-inflammatory pathways between type 2 diabetes and Parkinson’s mean drugs that work for one might help the other. A 2026 network meta-analysis pooled 5 trials and 708 patients. Pairwise analysis showed no …